<DOC>
	<DOCNO>NCT01018303</DOCNO>
	<brief_summary>The purpose study test safety efficacy final commercial formulation antioxidant enrich multivitamin supplement softgel capsule form ( AquADEKs ) increase plasma level certain nutrient antioxidant individual cystic fibrosis . Hypothesis : An oral antioxidant-rich multivitamin supplement ( AquADEKs ) , use Generally Regarded As Safe ( GRAS ) molecule form micelle-like vehicle , safely increase systemic level beta-carotene , coenzyme Q10 , gamma-tocopherol , decrease PIVKA-II level , maintain level vitamins A D normal range person CF &gt; 10 year age .</brief_summary>
	<brief_title>Safety Efficacy Antioxidant-rich Multivitamin Supplement Cystic Fibrosis</brief_title>
	<detailed_description>In cystic fibrosis ( CF ) , pancreatic insufficiency diminish bile acid pool cause malabsorption important nutrient dietary component lead poor nutritional status oxidative stress . Of particular significance malabsorption fat-soluble nutrient , vitamins A , D , E K critical normal metabolic function . Furthermore malabsorption prevents individual CF adequately absorb maintain level lipophilic nutrient antioxidant beta-carotene , coenzyme Q10 ( CoQ10 ) gamma-tocopherol may provide benefit supply level higher obtain normal diet . Current standard care supplementation often normalize blood level certain vitamin antioxidant . An oral formulation , form micelle-like vehicle , use overcome malabsorption nutrient CF patient . A pilot study prototype formulation show safety efficacy increase systemic level target nutrient . This study test safety efficacy final commercial formulation ( AquADEKs ) form softgel capsule increase plasma level certain nutrient antioxidant . Hypothesis : An oral antioxidant-rich multivitamin supplement ( AquADEKs ) , use Generally Regarded As Safe ( GRAS ) molecule form micelle-like vehicle , safely increase systemic level beta-carotene , coenzyme Q10 , gamma-tocopherol , decrease PIVKA-II level , maintain level vitamins A D normal range person CF &gt; 10 year age . Specific Aims : 1 . To evaluate safety AquADEKs monitoring patient report symptoms adverse event , follow vitamin antioxidant level , particularly vitamin A , ensure exceed normative range supplementation . 2 . To determine efficacy AquADEKs increase antioxidant beta-carotene , CoQ10 , γ-tocopherol maintain plasma level vitamins A , D , α-tocopherol PIVKA-II ( surrogate vitamin K status ) normal range .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>Diagnosis CF evidence sweat chloride test &gt; 60mEq/L presence two know CF mutation Male female , age 1040 year old &gt; 30 kg body weight FEV1 &gt; 35 % predict age height Clinically stable recent hospitalization within past 2 week Significant liver disease define clinical finding portal hypertension cirrhosis AST , ALT , GGT &gt; 2x upper limit normal within previous 6 month Poor compliance medical regimen assess CF clinic care provider Oral supplementation AquADEKs another source betacarotene CoQ10 2 month prior study Pregnant lactate Participation another interventional clinical trial within previous 2 week Difficulty swallow softgels</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>vitamin</keyword>
	<keyword>antioxidant</keyword>
	<keyword>anthropometric measurement</keyword>
	<keyword>pulmonary function</keyword>
</DOC>